EarlyTect BCD Plus: A urine‐based dual site PENK methylation test for risk‐based cystoscopy triage in haematuria

20260 citationsJournal Articlegold Open Access

Authors

Tae Jeong Oh · Genome Research Foundation

Bo‐Ram Bang · Promentis Pharmaceuticals (United States)

Jae Hee Hwang · Genome Research Foundation

Yangyei Seo · Genome Research Foundation

Seoyong Kim · Promentis Pharmaceuticals (United States)

Sujin Gu · Promentis Pharmaceuticals (United States)

Safedin Beqaj

Abstract

EarlyTect BCD Plus significantly enhances detection of Ta-LG bladder cancer while maintaining high specificity. Its high NPV supports use as a non-invasive adjunct and triage tool, allowing deferral of cystoscopy in selected haematuria patients.

Topics & Keywords

Pediatric Urology and Nephrology Studies Bladder and Urothelial Cancer Treatments Ureteral procedures and complications

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: BJUI Compass

Volume 7, Issue 3, pp. e70178-e70178

DOI: 10.1002/bco2.70178

Field-Weighted Citation Impact: 0.00